Resolution of inverse psoriasis after treatment with levodopa for Parkinson's disease

Suárez, Natalia Rojo; Jiménez‐Gallo, David; Aguilera, Cintia Arjona; Espinosa-Rosso, Raúl; Linares‐Barrios, Mario

doi:10.1111/dth.12408

Cited by 4 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A relationship between DA and the pathophysiology of psoriasis has been known since the 1970s. Thus, levodopa resulted in the resolution of inverse psoriasis when being used for Parkinson’s disease, possibly due to an increase in cyclic AMP 50. Moreover, bromocriptine, a strong D2R agonist, has been used in patients with psoriasis with different results on the clinical outcome 51–53…”

Section: Therapeutic Neurotransmitter Targetsmentioning

confidence: 99%

<p>Psoriasis and alcohol</p>

Svanstrom¹,

Lonne-Rahm²,

Nordlind³

2019

PTT

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease that may be triggered or worsened by several factors, including alcohol. A higher than average alcohol consumption is common among individuals with psoriasis. Neurobiological signaling affected by alcohol intake includes a range of neurotransmitters, such as the dopaminergic, serotonergic, and tachykinergic systems, involved in reward and drug-seeking. These neurotransmitters may also have an impact on the inflammatory processes per se in psoriasis. Future therapy may, therefore, be targeted at neurotransmitter networks involved with both alcohol intake and the inflammatory processes.

show abstract

Section: Therapeutic Neurotransmitter Targetsmentioning

confidence: 99%

<p>Psoriasis and alcohol</p>

Svanstrom¹,

Lonne-Rahm²,

Nordlind³

2019

PTT

View full text Add to dashboard Cite

show abstract

“…Rojo Suárez et al described a case report of a patient with intertriginous psoriasis, resistant to standard therapy, and PD who was prescribed levodopa. First, they observed gradual improvement of skin and neurological condition and later relapse when the patient stopped taking her medications and again the resolution of skin lesions after reintroduction of levodopa (Rojo Suárez et al, 2017 ). Moreover, they discussed several similar studies.…”

Section: Discussionmentioning

confidence: 99%

“…We found four reports where resolution or improvement in psoriatic skin lesions was observed after administration of levodopa (Barbeau, 1970;Barbeau and Giroux, 1972;Giroux et al, 1972;Rojo Suárez et al, 2017). Levodopa is a dopaminergic drug used as a first-line treatment option for PD (Hayes, 2019).…”

Section: The E Cacy Of Common Drugs In the Treatment Of Psoriasis And...mentioning

confidence: 99%

Psoriasis and neurodegenerative diseases—a review

Nowowiejska

Baran

Flisiak

2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Psoriasis is a chronic skin disease with underlying genetic, inflammatory and immunological background, which is a great medical problem, currently regarded as a systemic condition. Neurodegenerative diseases (NDs) are characterized by a progressive loss of nervous tissue, which affects elderly people more frequently; therefore, it is suspected that, due to society's aging, morbidity is going to increase. We performed a thorough review in order to investigate for the first time whether psoriasis may predispose to different particular neurodegenerative diseases—Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). PubMed search resulted in the retrieval of 833 records, of which 77 eligible were included in the review. Our thorough analysis revealed there are some potential links between psoriasis and NDs (inflammation, oxidative stress, genetics, cardiometabolic disorders), but there is no strong evidence that psoriasis may predispose to NDs. Based on the evidence, it seems that the risk of PD in psoriatics is not increased, and the evidence for increased risk of AD slightly prevails the data that state the opposite. ALS risk does not seem to be increased in psoriatics. The paucity of original studies does not allow for the formulation of definitive conclusions but encourages to perform further investigations.

show abstract

Dopamine, Immunity, and Disease

et al. 2022

View full text Add to dashboard Cite

The neurotransmitter dopamine is a key factor in central nervous system (CNS) function, regulating many processes including reward, movement, and cognition. Dopamine also regulates critical functions in peripheral organs, such as blood pressure, renal activity, and intestinal motility. Beyond these functions, a growing body of evidence indicates that dopamine is an important immunoregulatory factor. Most types of immune cells express dopamine receptors and other dopaminergic proteins, and many immune cells take up, produce, store, and/or release dopamine, suggesting that dopaminergic immunomodulation is important for immune function. Targeting these pathways could be a promising avenue for the treatment of inflammation and disease, but despite increasing research in this area, data on the specific effects of dopamine on many immune cells and disease processes remain inconsistent and poorly understood. Therefore, this review integrates the current knowledge of the role of dopamine in immune cell function and inflammatory signaling across systems. We also discuss the current understanding of dopaminergic regulation of immune signaling in the CNS and peripheral tissues, highlighting the role of dopaminergic immunomodulation in diseases such as Parkinson’s disease, several neuropsychiatric conditions, neurologic human immunodeficiency virus, inflammatory bowel disease, rheumatoid arthritis, and others. Careful consideration is given to the influence of experimental design on results, and we note a number of areas in need of further research. Overall, this review integrates our knowledge of dopaminergic immunology at the cellular, tissue, and disease level and prompts the development of therapeutics and strategies targeted toward ameliorating disease through dopaminergic regulation of immunity. Significance Statement Canonically, dopamine is recognized as a neurotransmitter involved in the regulation of movement, cognition, and reward. However, dopamine also acts as an immune modulator in the central nervous system and periphery. This review comprehensively assesses the current knowledge of dopaminergic immunomodulation and the role of dopamine in disease pathogenesis at the cellular and tissue level. This will provide broad access to this information across fields, identify areas in need of further investigation, and drive the development of dopaminergic therapeutic strategies.

show abstract

Resolution of inverse psoriasis after treatment with levodopa for Parkinson's disease

Cited by 4 publications

References 6 publications

<p>Psoriasis and alcohol</p>

<p>Psoriasis and alcohol</p>

Psoriasis and neurodegenerative diseases—a review

Dopamine, Immunity, and Disease

Contact Info

Product

Resources

About